At Keryx, the patient comes first. Our goal is to bring innovative therapies to market that provide unique and meaningful advantages to patients with renal disease and their healthcare providers – because we know that

when patient care improves, everybody succeeds.

CDC estimates that more than 10% of adults in the United States—more than 20 million people—may have CKD.

You are leaving

You are leaving, a website of Keryx Biopharmaceuticals, Inc. Keryx does not review or control the content of non-Keryx websites, and this hyperlink does not constitute an endorsement by Keryx of the site’s content. Keryx’s privacy procedures do not apply to the owners of a non-Keryx website.